Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...
Business Wire6h
6sense Releases State of the BDR 2025 Research Report, Revealing AI's Positive Impact on Sales Development
SAN FRANCISCO-- ( BUSINESS WIRE )-- 6sense ®, the leading platform revolutionizing B2B revenue generation, today released its ...
UBS maintains Alvotech stock Buy rating, $18 target
UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...
Bridgeline targets AI-driven growth with reallocation to sales and marketing in 2025
Q1 2025 Management View CEO Ari Kahn announced a strategic shift to focus on sales and marketing, reallocating resources from R&D to capitalize on market demand for the company’s AI-powered products.